Notes to Financial Statements
7) Other operating charges
|
2006 £'000 |
Restated 2005 £'000 |
|---|---|---|
Laboratory consumables and services |
23,490 |
23,323 |
Supplies and services |
39,187 |
37,614 |
Accommodation |
19,605 |
17,126 |
Travel and subsistence |
4,366 |
4,296 |
Auditor's remuneration |
140 |
121 |
Bad and doubtful debt provision |
296 |
173 |
Losses and gains on disposal of tangible fixed assets |
25 |
240 |
Impairment of tangible fixed assets |
- |
398 |
Total other operating charges |
87,109 |
83,291 |
8) Exceptional Items
The Agency inherited liabilities relating to staff who had taken early retirement or redundancy from two of its predecessor bodies, the Public Health Laboratory Services and the National Radiological Protection Board. Following an actuarial valuation carried out by the Government Actuary's Department as at 31 March 2006, the provision for these liabilities was increased by £3,257,000. This increase has been charged to the income and expenditure account for the year ending 31 March 2006 as an exceptional item in accordance with Financial Reporting Standard 3.
9) Intangible fixed assets
|
Software licences £'000 |
|---|---|
Cost or valuation |
|
At 1 April 2005 (restated) |
1,366 |
Additions |
- |
Disposals |
(8) |
At 31 March 2006 |
1,358 |
Amortisation |
|
At 1 April 2005 (restated) |
182 |
Charge for year |
249 |
Disposals |
(4) |
At 31 March 2006 |
427 |
Net book value |
|
At 31 March 2006 |
931 |
At 31 March 2005 (restated) |
1,184 |
10) Tangible fixed assets
|
Land and buildings |
Fixtures & fittings |
Plant & equipment |
Information technology equipment |
Vehicles |
Assets under construction |
Total |
|---|---|---|---|---|---|---|---|
|
£'000 |
£'000 |
£'000 |
£'000 |
£'000 |
£'000 |
£'000 |
Cost or valuation |
|
|
|
|
|
|
|
At 1 April 2005 (restated) |
109,433 |
- |
17,789 |
4,881 |
176 |
7,905 |
140,184 |
Additions |
- |
- |
272 |
23 |
10 |
15,278 |
15,583 |
Transfer of assets brought into use |
5,344 |
1,869 |
1,358 |
1,485 |
- |
(10,056) |
- |
Revaluations |
2,623 |
8 |
426 |
1 |
2 |
- |
3,060 |
Disposals |
- |
- |
(342) |
- |
- |
- |
(342) |
At 31 March 2006 |
117,400 |
1,877 |
19,503 |
6,390 |
188 |
13,127 |
158,485 |
Depreciation |
|
|
|
|
|
|
|
At 1 April 2005 (restated) |
2,913 |
- |
5,132 |
1,728 |
52 |
- |
9,825 |
Charge for year |
5,830 |
32 |
2,584 |
1,052 |
33 |
- |
9,531 |
Disposals |
- |
- |
(176) |
- |
- |
- |
(176) |
At 31 March 2006 |
8,743 |
32 |
7,540 |
2,780 |
85 |
- |
19,180 |
Net book value |
|
|
|
|
|
|
|
At 31 March 2006 |
108,657 |
1,845 |
11,963 |
3,610 |
103 |
13,127 |
139,305 |
At 31 March 2005 (restated) |
106,520 |
- |
12,657 |
3,153 |
124 |
7,905 |
130,359 |
Land and buildings
Freehold land and buildings have a net book value of £108,421,000 (2005: £106,284,000), leasehold land and buildings have a net book value of £236,000 (2005: £236,000).
Merger adjustments
The above note includes an adjustment to asset values arising from the need to ensure the accounting policies of the merged bodies are aligned. Full details are contained in note 25.
Third party owned assets
In addition to the above tangible fixed assets, the Agency held tangible fixed assets with a total cost of £980,000 (2005: £568,000) which were funded and remain in the ownership of third parties. These assets consisted of a modular building (£436,000) and plant and equipment (£544,000).
Restatement of opening values
In line with Financial Reporting Standard 15, the opening values for tangible fixed assets cost or valuation and depreciation at 1 April 2005 have been restated. This has reduced both the cost or valuation and depreciation as at 1 April 2005 by £10,145,000. The net book value at 31 March 2005 is unchanged.
11) Investments
Investments comprise the Agency's 24.41% holding of ordinary shares of £0.001 in the issued share capital of Syntaxin Limited, acquired for a cash consideration of £1,232.50 on 10 November 2005. There is no easily ascertainable market value for the shareholdings, so the Board has opted to disclose the holdings on a historic cost basis. Consideration of the market value, if readily ascertainable, will be part of an ongoing review process. It is expected that the Health Protection Agency's holding in Syntaxin relative to that of other shareholders will reduce with time as the investors commit further finance to the company, contingent on Syntaxin continuing to meet the objectives outlined in its business plan.
